AlphaYou
Overview
8 funds hold it, insiders have been net selling, and 10 straight earnings beats.
Key stats
Sep 7- Open
- $149.23
- 52-wk high
- $155.38
- High
- $151.19
- 52-wk low
- $106.44
- Low
- $149.23
- Prev close
- $151.22
- Mkt cap
- $187.23B
- Volume
- 6.18M
- Fwd P/E
- 15.4x
- Beta
- 0.35
- Div yield
- 2.13%
- P/S
- 6.2x
- P/B
- 15.8x
- Profit margin
- -10.6%
- Op margin
- +33.7%
- ROE
- -20.7%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 4.5% above what analysts expected.
Earnings per share
-$7.07 expected
Revenue
No comparable estimate
FY2026 guidance
$30.10B to $30.40B
No comparable estimate
Reports Oct 29, 2026, in 52 days
EPS expected
$1.90 to $2.68
Revenue expected
19 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $7.77B | $7.92B | $6.96B | $7.80B |
| Cost of what it sold | $1.57B | $1.62B | $1.45B | $1.58B |
| Gross profit | $6.20B | $6.30B | $5.51B | $6.22B |
| What it spent | ||||
| Research and development | $1.35B | $1.58B | $1.37B | $1.76B |
| Sales and admin | $528.0M | $652.0M | $553.0M | $1.92B |
| Other operating costs | $999.0M | $1.08B | $1.00B | $12.93B |
| Total operating expenses | $2.87B | $3.31B | $2.93B | $16.62B |
| What was left | ||||
| Operating profit | $3.33B | $2.99B | $2.69B | -$10.39B |
| Interest on debt | $256.0M | $255.0M | $240.0M | $247.0M |
| Profit before tax | $3.64B | $2.08B | $2.58B | -$10.25B |
| Tax | $589.0M | -$105.0M | $559.0M | $242.0M |
| Net profit | $3.05B | $2.18B | $2.02B | -$10.50B |
| EBITDA | $4.58B | $3.02B | $3.51B | -$10.01B |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
BullishSep 4TD Waterhouse Canada Inc. Sells 70,572 Shares of Gilead Sciences, Inc. $GILD
BullishSep 4NEOS Investment Management LLC Has $120.08 Million Position in Gilead Sciences, Inc. $GILD
Leans bullishSep 4AXQ Capital LP Makes New Investment in Gilead Sciences, Inc. $GILD
BullishSep 4Eikon Therapeutics names CP Chang as chief scientific officer By Investing.com
Leans bullishSep 3Gilead Sciences Inc. stock underperforms Thursday when compared to competitors despite daily gains
NeutralSep 3BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up - Here's Why
NeutralSep 3People on the Move: Kevin Lundquist Named Chief Financial Officer of Outlook Therapeutics
NeutralSep 3
Macro
30 macro signals shaping GILD right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results